On 9 November, Amylyx Pharmaceuticals, a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis, Alzheimer’s disease (AD) and other neurodegenerative diseases, announced that the last research participant has completed the planned 24 weeks in its Phase II PEGASUS trial. The PEGASUS Phase II trial is a 24-week randomised, double-blind, multi-site and placebo-controlled study evaluating the safety and tolerability of AMX0035 in people with late mild cognitive impairment or early dementia due to AD. AMX0035 is a combination of existing compounds designed to prevent neuroinflammation and nerve cell death. The company completed the enrolment of this PEGASUS trial in June 2020. Top-line results from the trial are expected for the first half of 2021.
